United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of Company Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction that occurred on Monday, October 12th. The stock was sold at an average price of $550.70, for a total value of $5,231,650.00. Following the transaction, the chief executive officer directly owned 324,443 shares in the company, valued at approximately $178,670,760.10. This trade represents a 2.84% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

United Therapeutics Trading Down 1.2%

Shares of UTHR traded down $6.70 during mid-day trading on Tuesday, reaching $543.40. The company’s stock had a trading volume of 504,426 shares, compared to its average volume of 554,931. United Therapeutics Corporation has a 1-year low of $409.07 and a 1-year high of $609.35. The stock has a market cap of $23.31 billion, a P/E ratio of 19.44, a PEG ratio of 2.73 and a beta of 0.49. The business has a 50-day simple moving average of $512.67 and a two-hundred day simple moving average of $540.26.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping the consensus estimate of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%. The company had revenue of $783.30 million during the quarter, compared to the consensus estimate of $804.65 million. During the same period in the previous year, the company posted $6.41 EPS. The firm’s revenue for the quarter was down 1.9% compared to the same quarter last year. Research analysts anticipate that United Therapeutics Corporation will post 26.40 EPS for the current year.

Institutional Investors Weigh In On United Therapeutics

Institutional investors have recently modified their holdings of the business. BlackRock Inc. purchased a new position in United Therapeutics during the 2nd quarter worth $2,868,735,000. Janus Henderson Group PLC raised its holdings in shares of United Therapeutics by 8.9% in the first quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock valued at $514,016,000 after purchasing an additional 70,829 shares during the last quarter. Jupiter Topco LLC purchased a new stake in shares of United Therapeutics in the second quarter valued at about $450,140,000. Swedbank AB raised its holdings in shares of United Therapeutics by 0.7% in the first quarter. Swedbank AB now owns 327,122 shares of the biotechnology company’s stock valued at $193,977,000 after purchasing an additional 2,350 shares during the last quarter. Finally, Pictet Asset Management Holding SA lifted its position in shares of United Therapeutics by 0.8% during the first quarter. Pictet Asset Management Holding SA now owns 309,220 shares of the biotechnology company’s stock valued at $183,306,000 after purchasing an additional 2,383 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on UTHR. JPMorgan Chase & Co. upped their price objective on shares of United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a report on Thursday, July 23rd. Royal Bank Of Canada upped their price target on shares of United Therapeutics from $677.00 to $708.00 and gave the company an “outperform” rating in a research note on Thursday, October 8th. The Goldman Sachs Group assumed coverage on shares of United Therapeutics in a report on Thursday, September 24th. They issued a “sell” rating and a $321.00 price target on the stock. Bank of America decreased their target price on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. Finally, Morgan Stanley increased their target price on United Therapeutics from $515.00 to $566.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 7th. Eleven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $627.31.

About United Therapeutics

United Therapeutics Corporation is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH) and other serious cardiopulmonary conditions. The company’s products include Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable form of treprostinil; Orenitram, an oral treprostinil product; and Adcirca, a tadalafil-based PAH treatment.

United Therapeutics markets its therapies primarily in the United States and internationally through commercial and regulatory activities in additional markets.